MX2016004702A - Polipeptidos del factor vii de coagulacion. - Google Patents
Polipeptidos del factor vii de coagulacion.Info
- Publication number
- MX2016004702A MX2016004702A MX2016004702A MX2016004702A MX2016004702A MX 2016004702 A MX2016004702 A MX 2016004702A MX 2016004702 A MX2016004702 A MX 2016004702A MX 2016004702 A MX2016004702 A MX 2016004702A MX 2016004702 A MX2016004702 A MX 2016004702A
- Authority
- MX
- Mexico
- Prior art keywords
- factor vii
- vii polypeptides
- coagulation factor
- variants
- substitutions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a polipéptido del Factor VII de coagulación humano modificado que tiene actividad coagulante, especialmente variantes que tienen mayor actividad proteolítica y reactividad antitrombina reducida (resistencia incrementada en la activación por antitrombina) cuando se activan como son comparados con el FVIIa de tipo natural. Las variantes tienen ciertas sustituciones en la posición T293 del FVII humano maduro en combinación con sustituciones específicas en L288, W201 y/o K337. Las reivindicaciones también se dirigen a las composiciones farmacéuticas, y usos médicos de los polipéptido del factor VII.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13188715 | 2013-10-15 | ||
US201361895438P | 2013-10-25 | 2013-10-25 | |
EP14154875 | 2014-02-12 | ||
PCT/EP2014/072076 WO2015055692A1 (en) | 2013-10-15 | 2014-10-15 | Coagulation factor vii polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016004702A true MX2016004702A (es) | 2016-07-22 |
Family
ID=52810172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016004702A MX2016004702A (es) | 2013-10-15 | 2014-10-15 | Polipeptidos del factor vii de coagulacion. |
Country Status (11)
Country | Link |
---|---|
US (4) | US9371370B2 (es) |
EP (1) | EP3058066A1 (es) |
JP (1) | JP2016537321A (es) |
KR (1) | KR20160065925A (es) |
CN (1) | CN105637088A (es) |
AU (1) | AU2014336252A1 (es) |
BR (1) | BR112016008039A2 (es) |
CA (1) | CA2927756A1 (es) |
IL (1) | IL244594A0 (es) |
MX (1) | MX2016004702A (es) |
WO (1) | WO2015055692A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015533152A (ja) * | 2012-10-15 | 2015-11-19 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 第vii因子コンジュゲート |
KR20160065925A (ko) | 2013-10-15 | 2016-06-09 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 응고 인자 vii 폴리펩티드 |
AR099340A1 (es) * | 2014-02-12 | 2016-07-13 | Novo Nordisk As | Conjugados del factor de coagulación ix |
AR101060A1 (es) * | 2014-02-12 | 2016-11-23 | Novo Nordisk As | Conjugados de fviii |
RU2022102624A (ru) * | 2015-10-01 | 2022-03-10 | Хит Байолоджикс, Инк. | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков |
KR20210094293A (ko) | 2020-01-21 | 2021-07-29 | 김수호 | 차량용 핸들 장치 및 이를 포함하는 차량운전 보조 시스템 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2325877T3 (es) | 2000-02-11 | 2009-09-23 | Bayer Healthcare Llc | Moleculas de tipo factor vii o viia. |
JP4361728B2 (ja) | 2000-09-13 | 2009-11-11 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト凝固因子vii変異型 |
US7235638B2 (en) | 2001-03-22 | 2007-06-26 | Novo Nordisk Healthcare A/G | Coagulation factor VII derivatives |
ES2516041T3 (es) | 2001-10-10 | 2014-10-30 | Ratiopharm Gmbh | Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH) |
JP2007501811A (ja) | 2003-08-08 | 2007-02-01 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。 |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
WO2005075635A2 (en) | 2004-02-03 | 2005-08-18 | Novo Nordisk Health Care Ag | Coagulation factor vii/viia variants lacking a functional lipid membrane binding domain |
JP5216580B2 (ja) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー/エス | グリコペグ化第ix因子 |
WO2006134174A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Dimeric and multimeric fviia compound |
JP2009515508A (ja) | 2005-08-19 | 2009-04-16 | ネオス テクノロジーズ インコーポレイテッド | グリコpeg化因子viiおよび因子viia |
JP5690047B2 (ja) | 2005-09-14 | 2015-03-25 | ノボ ノルディスク ヘルス ケア アーゲー | ヒト凝固第vii因子ポリペプチド |
US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
ES2521490T3 (es) | 2006-12-15 | 2014-11-12 | Baxter International Inc. | Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada. |
WO2008127702A2 (en) | 2007-04-13 | 2008-10-23 | Catalyst Biosciences, Inc. | Modified factor vii polypetides and uses thereof |
US9687559B2 (en) | 2008-03-19 | 2017-06-27 | The Board Of Regents Of The University Of Oklahoma | Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
WO2010030342A2 (en) | 2008-09-09 | 2010-03-18 | The Board Of Regents Of The University Of Oklahoma | Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
US20120093840A1 (en) | 2009-04-06 | 2012-04-19 | Novo Nordisk A/S | Targeted delivery of factor viii proteins to platelets |
JP2013517782A (ja) | 2010-01-28 | 2013-05-20 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 因子vii融合ポリペプチド |
WO2011101242A1 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
WO2011101277A1 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Conjugated proteins |
EP2593130A2 (en) | 2010-07-15 | 2013-05-22 | Novo Nordisk A/S | Stabilized factor viii variants |
EP2616486B1 (en) | 2010-09-15 | 2019-01-02 | Stichting Sanquin Bloedvoorziening | Factor viii variants having a decreased cellular uptake |
JP2015533152A (ja) | 2012-10-15 | 2015-11-19 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 第vii因子コンジュゲート |
JP2015532307A (ja) * | 2012-10-15 | 2015-11-09 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 凝固因子viiポリペプチド |
WO2014140103A2 (en) | 2013-03-12 | 2014-09-18 | Novo Nordisk A/S | Thrombin sensitive coagulation factor x molecules |
KR20160065925A (ko) | 2013-10-15 | 2016-06-09 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 응고 인자 vii 폴리펩티드 |
AR099328A1 (es) | 2014-02-12 | 2016-07-13 | Novo Nordisk As | Conjugados de factor vii |
-
2014
- 2014-10-15 KR KR1020167011328A patent/KR20160065925A/ko unknown
- 2014-10-15 BR BR112016008039A patent/BR112016008039A2/pt not_active Application Discontinuation
- 2014-10-15 AU AU2014336252A patent/AU2014336252A1/en not_active Abandoned
- 2014-10-15 CA CA2927756A patent/CA2927756A1/en not_active Withdrawn
- 2014-10-15 WO PCT/EP2014/072076 patent/WO2015055692A1/en active Application Filing
- 2014-10-15 MX MX2016004702A patent/MX2016004702A/es unknown
- 2014-10-15 CN CN201480057038.0A patent/CN105637088A/zh not_active Withdrawn
- 2014-10-15 EP EP14786841.8A patent/EP3058066A1/en not_active Withdrawn
- 2014-10-15 US US14/514,794 patent/US9371370B2/en not_active Expired - Fee Related
- 2014-10-15 JP JP2016523306A patent/JP2016537321A/ja not_active Withdrawn
-
2015
- 2015-11-09 US US14/936,224 patent/US9370583B2/en not_active Expired - Fee Related
-
2016
- 2016-03-14 IL IL244594A patent/IL244594A0/en unknown
- 2016-05-18 US US15/158,060 patent/US20170096655A1/en not_active Abandoned
-
2018
- 2018-01-17 US US15/873,236 patent/US20180142227A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20150105321A1 (en) | 2015-04-16 |
CA2927756A1 (en) | 2015-04-23 |
AU2014336252A1 (en) | 2016-04-07 |
CN105637088A (zh) | 2016-06-01 |
WO2015055692A1 (en) | 2015-04-23 |
US20160120992A1 (en) | 2016-05-05 |
IL244594A0 (en) | 2016-04-21 |
JP2016537321A (ja) | 2016-12-01 |
BR112016008039A2 (pt) | 2017-10-17 |
US9370583B2 (en) | 2016-06-21 |
US20180142227A1 (en) | 2018-05-24 |
KR20160065925A (ko) | 2016-06-09 |
EP3058066A1 (en) | 2016-08-24 |
US20170096655A1 (en) | 2017-04-06 |
US9371370B2 (en) | 2016-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016004702A (es) | Polipeptidos del factor vii de coagulacion. | |
BR112014003109A2 (pt) | variantes de plasminogênio e plasmina | |
MX2010003095A (es) | Antidotos para inhibidores del factor xa y metodos para usar los mismos. | |
MX2013007791A (es) | Variantes de plasminogeno y plasmina. | |
PE20151727A1 (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c | |
MX2015011466A (es) | Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora. | |
MX2012000475A (es) | Variantes de plasminogeno y plasmina. | |
MX2011009539A (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso. | |
EP2767587A3 (en) | Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders | |
WO2015086406A3 (en) | Factor ix variants with clotting activity in absence of their cofactor and/or with increased f.ix clotting activity and their use for treating bleeding disorders | |
MX2012012684A (es) | Factor villa viia conjugado para coagulacion de la sangre. | |
MX2013014543A (es) | Tratamiento de trastornos de la coagulacion mediante la administracion del factor von willebrand (vwf) recombinante. | |
IN2012DN02471A (es) | ||
UA113849C2 (xx) | Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу | |
WO2014140103A3 (en) | Thrombin sensitive coagulation factor x molecules | |
UA107687C2 (ru) | Комбинированная композиция, которая в качестве активных ингредиентов содержит l-карнитин или пропионил-l-карнитин, троксерутин, диосмин и гесперидин, для предотвращения и/или лечения хронических заболеваний вен. | |
GEP201606514B (en) | Apoptosis inhibitors and usage thereof | |
GB2492908A (en) | Novel uses of elafin | |
EA201390955A1 (ru) | Слитый белок robo1-fc для применения в лечении гепатокарциномы | |
MX2011009277A (es) | Composicion de leucocito activada. | |
IN2014CN04861A (es) | ||
DK2175877T3 (da) | Anvendelse af muterede antitrombiner til behandling eller forebyggelse af koagulationssygdomme | |
MX343784B (es) | Factor ii y fibrinogeno para tratamiento de trastornos hemostaticos. | |
MX2016003871A (es) | Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion. | |
MX2015009348A (es) | Composiciones hemostaticas. |